Influence of histologic subtype of small cell carcinoma of the lung on clinical presentation, response to therapy, and survival.
Influence of histologic subtype of small cell carcinoma of the lung on clinical presentation, response to therapy, and survival.
复制标题
小细胞肺癌的组织学亚型对临床表现、治疗反应和生存的影响。
DOI：
10.1093/jnci/65.6.1225
复制
发表时间：
1980
期刊：
影响因子：
--
通讯作者：
J. Minna
中科院分区：
文献类型：
--
作者：
D. Carney;M. Matthews;D. Ihde;P. Bunn;M. Cohen;R. Makuch;A. Gazdar;J. Minna
根据肺癌治疗工作组分类，对肺小细胞癌（SCCL）患者进行组织学亚型分型，并接受联合化疗。在研究的103例患者中，54例为淋巴细胞样（燕麦细胞）亚型，41例为中间细胞亚型，8例为两者的混合物。组织学亚型之间在初始体能状态、疾病程度、化疗反应率或生存期（中位数，10.2个月）方面无显著差异。当将原发活检组织的组织学亚型与同一患者的其他病理学标本的亚型进行比较时，74%的患者存在亚型一致性。在其余的26%中，存在两种或三种组织学亚型。这项研究表明，在广泛分期和接受积极细胞毒治疗的患者中，SCCL的各种组织学亚型之间没有临床显著差异。由于这一点，并且由于同一患者多个部位的并行活检组织可能在亚型上有所不同，我们得出结论，预后或治疗决策不应基于SCCL亚型。
Patients with small cell carcinoma of the lung (SCCL) were histologically subtyped according to the Working Party for Therapy of Lung Cancer classification and were treated with combination chemotherapy. Of the 103 patients studied, 54 had the lymphocyte-like (oat cell) subtype, 41 had the intermediate cell subtype, and 8 had a mixture of the two. No significant difference in initial performance status, extent of disease, chemotherapeutic response rate, or survival (median, 10.2 mo) was noted among the histologic subtypes. When the histologic subtype of the primary biopsy tissue was compared with the subtype of other pathology specimens from the same patient, concordance of subtype was present in 74% of the patients. In the remaining 26%, two or three histologic subtypes were present. This study demonstrates no clinically significant differences among the various histologic subtypes of SCCL in patients extensively staged and treated with aggressive cytotoxic therapy. Because of this and because concurrent biopsy tissues from multiple sites in the same patient may vary in subtype, we conclude that prognostic or therapeutic decisions should not be based on SCCL subtype.